Treatment of Migraine Attacks with Sumatriptan
Author:
- The Subcutaneous Sumatriptan International Study Group*TGThe Subcutaneous Sumatriptan International Study Group*
Open Access
- 1 August 1991
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 325 (5) , 316-321
Abstract
The headache in migraine attacks may be caused by dilatation of certain cranial arteries or arteriovenous anastomoses, by neurogenic dural plasma extravasation, or by both of these mechanisms. Sumatriptan, a novel selective agonist of 5-hydroxytryptamine—like receptors, blocks these phenomena. We investigated its efficacy in migraine.Keywords
This publication has 19 references indexed in Scilit:
- The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura materBritish Journal of Pharmacology, 1990
- Correlates of Headache in a Population-Based Cohort of ElderlyArchives of Neurology, 1989
- Serotonin metabolism in migraineNeurology, 1989
- 5-HT1-like receptor agonists and the pathophysiology of migraineTrends in Pharmacological Sciences, 1989
- An epidemiologic study of headache among adolescents and young adults1989
- Horner's Syndrome Sweat Gland and Pupillary Responsiveness in Two Cases with a Probable 3Rd Neurone DysfunctionCephalalgia, 1989
- Muscle Contraction Headache and Migraine: Platelet Activation and Plasma Norepinephrine During the Cold Pressor TestCephalalgia, 1989
- A Controlled Study of Dihydroergotamine in the Treatment of Acute Migraine HeadacheHeadache: The Journal of Head and Face Pain, 1986
- Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster HeadacheClinical Pharmacokinetics, 1985
- Cardiac Migraine—Report of Twelve CasesAngiology, 1974